| Asthma
Advair HFA vs Dupixent
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Advair Hfa vs Dupixent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDupixent has a higher rate of injection site reactions vs Advair Hfa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dupixent but not Advair Hfa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Advair Hfa
Dupixent
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
SC injection
Every 2 weeks
IL-4Ra antagonist
Indications
- Asthma
- Dermatitis, Atopic
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Eosinophilic esophagitis
- Prurigo nodularis
- Chronic Obstructive Airway Disease
- Chronic Spontaneous Urticaria
- Bullous pemphigoid
- Allergic Fungal Rhinosinusitis
Dosing
Asthma 2 oral inhalations (45 mcg/21 mcg, 115 mcg/21 mcg, or 230 mcg/21 mcg) twice daily approximately 12 hours apart; starting strength based on asthma severity; maximum 2 inhalations of 230 mcg/21 mcg twice daily.
Dermatitis, Atopic Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric patients 6 months to 5 years: weight-based Q4W without loading dose; pediatric patients >=6 years: weight-based loading dose then Q2W or Q4W.
Asthma Adults and pediatric >=12 years: 400 mg or 600 mg loading dose, then 200 mg or 300 mg SC Q2W; pediatric 6-11 years: weight-based Q2W or Q4W without loading dose.
Chronic rhinosinusitis with multiple nasal polyps 300 mg SC Q2W for adults and pediatric patients >=12 years.
Eosinophilic esophagitis SC weight-based dosing for patients >=1 year weighing >=15 kg: 200 mg Q2W (15 to <30 kg), 300 mg Q2W (30 to <40 kg), or 300 mg weekly (>=40 kg).
Prurigo nodularis Adults: 600 mg initial dose, then 300 mg SC Q2W.
Chronic Obstructive Airway Disease Adults: 300 mg SC Q2W.
Chronic Spontaneous Urticaria Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric 12-17 years: weight-based 400 mg or 600 mg loading, then 200 mg or 300 mg Q2W.
Bullous pemphigoid Adults: 600 mg initial dose, then 300 mg SC Q2W in combination with a tapering course of oral corticosteroids.
Allergic Fungal Rhinosinusitis Adults: 300 mg SC Q2W; pediatric 6-17 years: weight-based Q2W or Q4W (15 to <30 kg: 300 mg Q4W; 30 to <60 kg: 200 mg Q2W; >=60 kg: 300 mg Q2W).
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Hypersensitivity to any ingredient of ADVAIR HFA
- Known hypersensitivity to dupilumab or any excipients of DUPIXENT
Adverse Reactions
Most common (>=3%) Upper respiratory tract infection, throat irritation, headache, nausea and vomiting, musculoskeletal pain, upper respiratory inflammation, viral respiratory infection, hoarseness/dysphonia, dizziness, viral gastrointestinal infection, gastrointestinal signs and symptoms, muscle pain
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD patients, immunosuppression and risk of infections, hypercorticism and adrenal suppression, cardiovascular and CNS effects, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing Arrhythmias, hypertension, ventricular tachycardia, Cushing's syndrome, osteoporosis, cataracts, glaucoma, anaphylaxis, esophageal candidiasis, paradoxical bronchospasm, agitation, depression
Most common (>=1%) Injection site reactions, conjunctivitis, oral herpes, blepharitis, keratitis, eye pruritus, other herpes simplex virus infection, dry eye
Serious Hypersensitivity reactions, conjunctivitis and keratitis, psoriasis, arthralgia and psoriatic arthritis, parasitic (helminth) infections
Postmarketing Angioedema, psoriatic arthritis, facial skin reactions (erythema, rash, scaling, edema, papules, pruritus, burning, pain), new-onset psoriasis, vasculitis
Pharmacology
ADVAIR HFA combines fluticasone propionate, a synthetic trifluorinated corticosteroid with broad anti-inflammatory activity via glucocorticoid receptor binding, and salmeterol, a selective long-acting beta2-adrenoceptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase to increase cyclic AMP levels.
Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes, blocking cytokine-induced inflammatory responses including release of proinflammatory cytokines, chemokines, nitric oxide, and IgE.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Advair Hfa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (12/12)
Dupixent
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (2/12)
UnitedHealthcare
Advair Hfa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (5/8)
Dupixent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Humana
Advair Hfa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Dupixent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Advair Hfa.
Cost estimate not availableHealthWell Foundation: Asthma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Advair HfaView full Advair Hfa profile
DupixentView full Dupixent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.